Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.02 on Wednesday. The firm has a market capitalization of $196,951.30, a P/E ratio of -0.02 and a beta of 0.74. Bellerophon Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.02. The company’s fifty day moving average price is $0.04 and its 200-day moving average price is $0.04.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.